Insmed Incorporated
INSM
Kedudukan dalam Saham
#1101
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Harga Saham
$96.65
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$21.11B
Perubahan (1 hari)
-2.59%
Perubahan (1 tahun)
-41.70%
Negara
US
Perdagangan Insmed Incorporated (INSM)
Kategori
Healthcare
EPS untuk Insmed Incorporated (INSM)
EPS setakat June 2026 TTM: $-4.11
Menurut laporan kewangan terkini dan harga saham Insmed Incorporated, EPS semasa syarikat (TTM) adalah $-4.11. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-5.34 peningkatan berbanding EPS tahun 2022 iaitu $-3.91.
Sejarah EPS untuk Insmed Incorporated dari 2000 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-4.11 | -26.21% |
| 2024 | $-5.57 | 4.31% |
| 2023 | $-5.34 | 36.57% |
| 2022 | $-3.91 | 0.77% |
| 2021 | $-3.88 | 28.90% |
| 2020 | $-3.01 | 0.00% |
| 2019 | $-3.01 | -28.67% |
| 2018 | $-4.22 | 46.02% |
| 2017 | $-2.89 | 1.40% |
| 2016 | $-2.85 | 41.09% |
| 2015 | $-2.02 | 9.78% |
| 2014 | $-1.84 | 15.00% |
| 2013 | $-1.60 | 2.56% |
| 2012 | $-1.56 | -39.06% |
| 2011 | $-2.56 | 422.45% |
| 2010 | $-0.49 | -105.27% |
| 2009 | $9.30 | -826.56% |
| 2008 | $-1.28 | -26.44% |
| 2007 | $-1.74 | -70.46% |
| 2006 | $-5.89 | -29.88% |
| 2005 | $-8.40 | 20.86% |
| 2004 | $-6.95 | 140.48% |
| 2003 | $-2.89 | -73.75% |
| 2002 | $-11.01 | -2.65% |
| 2001 | $-11.31 | -74.06% |
| 2000 | $-43.60 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -521.41% |
US
|
|
| $-7.98 | 94.16% |
US
|
|
| $-5.29 | 28.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -774.94% |
NL
|
